We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mitochondrial Damage May Explain the Increased Incidence of Hypertension in Black Adults

By LabMedica International staff writers
Posted on 03 Mar 2022
Print article
Image: Monitoring blood pressure (Photo courtesy of 123rf.com)
Image: Monitoring blood pressure (Photo courtesy of 123rf.com)

Increased plasma concentration of the enzyme xanthine oxidase (XO) and the resulting mitochondrial DNA damage that it can cause may explain why Blacks have a significantly higher incidence of hypertension than their White counterparts.

Investigators at the University of Alabama (Birmingham, USA) had previously reported that increased plasma XO activity in patients with resistant hypertension could cause mitochondrial DNA damage and promote release of fragments called mitochondrial DNA damage-associated molecular patterns (mtDNA DAMPs). Xanthine oxidase is widely distributed in the heart, liver, gut, lung, kidney and brain, as well as in blood plasma. In its normal metabolic function, it generates oxygen radicals as a byproduct, including hydrogen peroxide and superoxide, which are reactive oxygen species that can damage DNA.

Considering that Black adults in the United States have one of the highest rates of hypertension in the world and have a 50% increased incidence of heart failure as compared to Whites, the investigators examined the importance of racial differences in XO activity and mtDNA DAMPs in adults with resistant hypertension.

The experimental cohort for this study included 91 resistant hypertension patients, 44% of whom were Black, and 37 controls with normal blood pressures. The resistant hypertension group all had blood pressures above 140/90 millimeters of mercury (mmHg), and all were on four or more medications for treatment of their high blood pressure.

Results revealed that Black resistant hypertension patients were younger (mean age 52±10 versus 59±10 years), with higher XO activity and left ventricular wall thickness, and worse diastolic dysfunction than White resistant hypertension patients. Urinary sodium excretion was positively related to left ventricular end-diastolic volume and left ventricular mass among Black but not White resistant hypertension patients. Patients with resistant hypertension had increased mtDNA DAMPs versus controls, with Black mtDNA DAMPS greater than Whites.

Transmission electron microscopy of skeletal muscle biopsies in resistant hypertension patients demonstrated mitochondrial damage such as cristae lysis, myofibrillar loss, large lipid droplets, and glycogen accumulation.

"Xanthine oxidase activation may set up a feed-forward cycle of mitochondrial damage, mitochondrial reactive oxygen species production, mtDNA DAMP release, and inflammation in the pathogenesis of hypertension end-organ injury," said senior author Dr. Louis J. Dell'Italia, professor emeritus of cardiovascular disease at the University of Alabama. "These results warrant a larger study that includes metabolic syndrome and xanthine oxidase as a potential therapeutic target to reduce mitochondrial damage and attenuate left ventricular diastolic dysfunction in Black adults with resistant hypertension. Although Black adults have the highest death rate for heart failure, they are consistently underrepresented in clinical trials. The greater heart failure burden among Black adults calls for further work to discover effective preventive and therapeutic strategies for this higher-risk population."

The study was published in the February 15, 2022, online edition of the journal Hypertension.

Related Links:
University of Alabama 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.